Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective

Table 1

Noninvasive methods for staging fibrosis in chronic hepatitis C.

Noninvasive method for estimation of liver fibrosis	Parameters
Biomarkers
APRI	AST and platelet count
ELF	PIIINP, TIMP-1, and hyaluronic acid
FIB-4	Platelet count, ALT and AST adjusted for age
FibroIndex	platelet count, AST, and gamma-globulin
FibroMeter	Alpha-2-macroglobulin, hyaluronic acid, platelet count, AST, prothrombin time, and urea adjusted for age
FibroSpect II	Hyaluronic acid, TIMP-1, and alpha-2-macroglobulin
FibroTest	Apolipoprotein A1, haptoglobin, alpha-2-macroglobulin, GGT, and total bilirubin adjusted for age and gender
Forns index	Platelet count, GGT, and total cholesterol adjusted for age and gender
HepaScore	Alpha-2-macroglobulin, GGT, total bilirubin, and hyaluronic acid adjusted for age and gender
Imaging techniques
AixPlorer	Real-time shear wave elastography
ARFI	Elastography
Fibroscan	Transient elastography
Magnetic Resonance Imaging	Elastography and water-diffusion abnormalities

ALT, alanine aminotransferase; AST, aspartate aminotransferase; ARFI, Acoustic Radiation Force Impulse; ELF, enhanced liver fibrosis; GGT, gamma-glutamyl transferase; PIIINP, serum amino-terminal propeptide of type III procollagen; TIMP-1, tissue inhibitors of matrix metalloproteinase.